Synchron raises US$200 million in Series D financing to advance BCI technology

Synchron Raises US$200 Million in Series D Funding to Advance BCI Technology

Synchron has secured US$200 million in a Series D funding round to drive the commercialisation of its first-generation Stentrode brain-computer interface (BCI) platform. The investment will also support the creation of a next-generation, transcatheter, high-channel whole-brain interface.

Funding and Strategic Goals

The company plans to accelerate pivotal clinical trials and prepare for the commercial launch of the Stentrode BCI system. With the new funds, Synchron aims to expand its team by hiring more engineers, neuroscientists, and operators to push forward the next generation of brain interface technologies.

“Bolstered by this Series D funding, Synchron will continue hiring engineers, neuroscientists and operators to advance the next generation of BCIs,” the company said in its press release.

Investors and Financial Overview

The Series D round was led by Double Point Ventures, with continued backing from ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS. New participants in the round include the Australian National Reconstruction Fund (NRF), T Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.

This latest investment brings Synchron’s total funding to US$345 million, according to the company’s latest announcement.

Author’s Summary

Synchron’s US$200 million Series D funding marks a major milestone in developing advanced brain-computer interface technology and expanding its global commercial ambitions.

more

NeuroNews International NeuroNews International — 2025-11-07

More News